title: Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
authors.affiliation: Mount Sinai School of Medicine, New York, NY 10028, USA. Electronic address: zbloom@gmail.com.
authors.forename: Zachary T
authors.initials: ZT
authors.lastname: Bloomgarden
mesh_terms: D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D008297:Male; D010455:Peptides / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D010455:Peptides; D014688:Venoms; D000069036:Insulin Glargine; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide